.png){kind=icon}
.png){kind=icon}
Return
How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease
.png){kind=icon}
PRE
AI
D
DOI：10.1038/s41571-026-01193-4.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
PROTEUS met its amended co-primary end points but should not be interpreted as practice changing. The trial compared two experimental strategies rather than the current standard of care, relied on an unvalidated approach (prostate-specific membrane antigen-PET) for assessments of metastasis-free survival, demonstrated minimal absolute benefit with increased toxicity and lacks both mature overall survival data and sufficient data on patient-reported outcomes to support adoption.
Journal
IF:
82.2
Papers:
2.3K
Citations:
3.3W
Organization
Cited Papers